Fennec Pharmaceuticals reported record third-quarter 2025 net product sales of $12.5 million for Pedmark, up 79% year over year, alongside positive cash flow from operations and a higher quarter-end cash balance of $21.9 million. The company flagged accelerating formulary adoption within a major U.S. oncology network and continued uptake across new and existing accounts. Preliminary readout from a Japanese investigator-initiated study (STS-J01) is expected in the fourth quarter of 2025, with a potential registration path in Japan to follow if results are favorable.
This is a telling moment for a niche oncology supportive care brand. Pedmark is carving out a commercially meaningful position in a market long defined by clinical need but minimal solutioning for cisplatin-induced ototoxicity. The gross margin profile implied by the low cost of product sales suggests operating leverage as volume scales. Yet the company’s reported “inflection point” comes with a nuance: GAAP financials still show a modest operating loss and a small net loss in the quarter, underscoring how growth, while real, remains finely balanced against spend. For commercial leaders, the lesson is that access and protocol wins can shift the revenue curve quickly in hospital-administered supportive therapies, but sustained profitability still hinges on disciplined field execution, payer alignment, and site-level operational fluency.
Why this matters now is straightforward. Cisplatin remains foundational across solid tumors, and hearing loss is a well-documented survivorship burden, particularly in pediatric and adolescent and young adult populations. A dedicated, on-label otoprotectant reframes conversations with pediatric oncologists, survivorship clinics, and payers around prevention rather than downstream assistive costs. Increased formulary placement within large provider networks can standardize ordering pathways, reduce friction in treatment planning, and normalize audiology monitoring. For payers, the value narrative is shifting from compassionate use to guideline-reinforced prevention with measurable downstream savings in devices, educational support, and long-term care. For competitors, this is a reminder that supportive care categories—once an afterthought—are becoming defendable brands when backed by compelling data, operational ease, and guideline endorsements.
The strategy extends beyond the U.S. The Norgine partnership has already put Pedmarqsi on the market in the U.K. and Germany, offering a lower-risk ex-U.S. growth vector while Fennec pursues Japan via an investigator-led study. The model blends targeted in-house commercialization, where the brand is most differentiated, with regional partnerships to compress time-to-revenue in complex markets. Medical Affairs is central to this playbook: investigator-initiated studies, KOL engagement, and real-world evidence generation will be critical to entrenching Pedmark as a standard component of cisplatin regimens and to supporting any future label expansion efforts. The rising volume of IIS proposals suggests a virtuous cycle where clinical curiosity and access gains reinforce one another.
The broader industry context is equally relevant. As hospital-administered oncology adjacencies become investable categories, more companies are likely to pursue narrowly defined but high-impact supportive care indications with clear operational advantages and strong health-economic logic. In an M&A-constrained environment, commercial momentum in these segments can invite selective partnering or royalty financing, particularly when coupled with long-dated IP and orphan or pediatric protections. The open question for 2026 is whether Fennec can translate network-level wins into durable, protocolized use across pediatric and AYA centers, while building the evidence and policy scaffolding to credibly approach adult cisplatin populations. If the Japan readout is positive and ex-U.S. uptake solidifies, Pedmark could become a case study in how focused supportive care assets scale beyond their initial niche without overextending the balance sheet.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
